Biochemical Discovery Intern

Brisbane, CA
Jan 06, 2022
Biotech Bay
Required Education
Associate Degree
Position Type
Full time
Mammoth is seeking a Biochemical Discovery Intern for the Summer with experience in basic biology and/or biochemistry wet lab techniques for its nuclease discovery team. The successful candidate will contribute to our efforts to biochemically characterize novel CRISPR-Cas systems with the ultimate goal of identifying unique and effective nucleases for therapeutic use. This is an excellent opportunity for students to learn about cutting edge CRISPR technologies in a fast-paced, growth-stage industry environment. 
  • Work directly with Scientists and Research Associates to biochemically characterize novel Cas proteins in terms of thermostability, target sensitivity, and other traits of interest
  • Assist in routine lab operations (reagent preparation, etc.)
  • Document work and be able to communicate findings and reasoning with other team members
  • The intern will specifically investigate the relationship between crispr RNA (crRNA) characteristics and protein function and activity 
  • The intern will learn/use basic wet lab techniques such as: PCR, plate based assays, bacterial culturing, cloning/transforming, and others as needed

  • Pursuing degree in molecular and cellular biology, biochemistry, or related field
  • Laboratory experience in biology or biochemistry through courses or undergraduate research

  • 1 year of academic part-time research or 1 Summer of previous lab internship experience
  • Curiosity and eagerness to learn about biological concepts and work in industry 

  • As CRISPR-Cas is a new and rapidly developing technology, no specific experience with CRISPR is required -- only a desire to learn! :) 

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law.  This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.